ZYME
NASDAQ:ZYMENASDAQ
7 announcements
Credibility Score56%
Zymeworks Announces Participation in Upcoming Investor Conferences
Routineunclear
Zymeworks schedules investor conference appearances but discloses no new financial or clinical data.
19 Nov 2026, 11:00 UTC
▼
Zymeworks Announces $200 Million Share Repurchase Authorization
OverhypedModerate hypeunclear
Zymeworks authorizes $200 million buyback, expects $140 million spent by 2028.
16 Nov 2026, 11:00 UTC
▼
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
OverhypedModerate hypeunclear
ZW191 shows strong Phase 1 efficacy but faces long-term development and funding hurdles.
24 Oct 2026, 06:30 UTC
▼
Zymeworks to Acquire Theravance Biopharma, Inc.
OverhypedModerate hypeimproving
Big promises, big price tag—real payoff is years away and far from guaranteed.
29 Jun 2026, 10:16 UTC
▼
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
OverhypedModerate hypeunclear
Promising early cancer data, but high toxicity and no financials mean caution is warranted.
14 Jun 2026, 22:14 UTC
▼
Zymeworks Announces Participation in Upcoming Investor Conferences
OverhypedModerate hypeunclear
Zymeworks offers big biotech promises but delivers little hard evidence for investors today.
13 May 2026, 10:14 UTC
▼
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
OverhypedModerate hypeunclear
21 Apr 2026, 21:43 UTC
▼